Sonnet Biotherapeutics Holdings Inc (SONN) - Total Liabilities
Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) has total liabilities worth $5.10 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Sonnet Biotherapeutics Holdings Inc growing its equity to track the company's year-over-year net asset growth rate.
Sonnet Biotherapeutics Holdings Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Sonnet Biotherapeutics Holdings Inc to measure how efficiently the company converts operating cash flow to free cash.
Sonnet Biotherapeutics Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Sonnet Biotherapeutics Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Auriginal Mining Corp.
V:AUME
|
Canada | CA$1.33 Million |
|
Green Rise Capital Corp
V:GRF
|
Canada | CA$48.75 Million |
|
Together Startup Network Ltd
TA:TGTR
|
Israel | ILA56.03 Million |
|
EV Resources Ltd
AU:EVR
|
Australia | AU$2.77 Million |
|
Total Transport Systems Limited
NSE:TOTAL
|
India | Rs1.01 Billion |
|
Ease2pay NV
AS:EAS2P
|
Netherlands | €3.21 Million |
|
Energy Development Company Limited
NSE:ENERGYDEV
|
India | Rs1.83 Billion |
|
Kim Hin Joo
KLSE:0210
|
Malaysia | RM23.55 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Sonnet Biotherapeutics Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SONN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sonnet Biotherapeutics Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sonnet Biotherapeutics Holdings Inc (2007–2025)
The table below shows the annual total liabilities of Sonnet Biotherapeutics Holdings Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $4.10 Million | +25.80% |
| 2024-09-30 | $3.26 Million | -42.41% |
| 2023-09-30 | $5.66 Million | -32.42% |
| 2022-09-30 | $8.37 Million | +24.28% |
| 2021-09-30 | $6.73 Million | +35.37% |
| 2020-09-30 | $4.97 Million | +72.41% |
| 2019-09-30 | $2.89 Million | -86.60% |
| 2018-12-31 | $21.54 Million | +15.20% |
| 2017-09-30 | $18.69 Million | -4.25% |
| 2016-09-30 | $19.52 Million | -4.52% |
| 2015-12-31 | $20.45 Million | -1.78% |
| 2015-09-30 | $20.82 Million | +135.29% |
| 2013-12-31 | $8.85 Million | 0.00% |
| 2013-09-30 | $8.85 Million | +129.04% |
| 2012-09-30 | $3.86 Million | -99.71% |
| 2011-09-30 | $1.33 Billion | +180982.33% |
| 2009-09-30 | $735.65K | +7.22% |
| 2008-09-30 | $686.12K | +96.45% |
| 2007-09-30 | $349.27K | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more